Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase inhibitor HBI-8000 has succeeded in combination with Bristol Myers Squibb’s Opdivo in a phase 3 trial of patients with advanced skin cancer.
Source: FiercePharma
